Ann: Becoming a substantial holder, page-36

A large number of Ph 3 trials fail on safety grounds. There is next to zero chance of that happening here.
There are also plenty of others that fail because there has been insufficent work done in Phase 2.
Here we have a very large Ph 2 study producing strong results overall and in key prespecified subgroups.
I think @Fernit's number (70%) is conservative.